Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 22,500 employees in 79 countries, and markets its products in 179 countries.
To view past issues of the HDP newsletter, please visit our archive.
If you know of anyone who would like to receive our regular email alerts, have them email us at updates@developmentprogram.org with their full name and contact details. If you no longer wish to receive updates email us at remove@developmentprogram.org.